Loading...
Most early drug-eluting stent (DES) trials did not include patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment–elevation MI (STEMI). The exclusions were, in part, because these patients tend to have lower restenosis rates than other patient groups and because of perceptions that the coated stents pose a slightly greater thrombosis risk than uncoated stents. Now, we have data from two DES trials that focus specifically on primary PCI in STEMI patients.
In a trial funded by the manufacturer of the FDA-approved sirolimus-eluting stent, 712 STEMI patients (16% diabetic) with symptom onset less than 12 hours before catheterization were randomized to receive that stent or an uncoated stent. Both groups had a mean re…